| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
21,479 |
18,967 |
$319K |
| 80346 |
|
3,185 |
2,952 |
$114K |
| 80356 |
|
3,185 |
2,953 |
$55K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,278 |
2,907 |
$50K |
| 80325 |
|
3,185 |
2,951 |
$45K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
408 |
361 |
$24K |
| 80368 |
|
1,508 |
1,423 |
$22K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,494 |
2,380 |
$21K |
| 80372 |
|
1,508 |
1,422 |
$17K |
| 80348 |
|
3,185 |
2,951 |
$8K |
| 80361 |
|
3,187 |
2,954 |
$8K |
| 80370 |
|
3,188 |
2,954 |
$8K |
| 80353 |
|
3,187 |
2,953 |
$8K |
| 80305 |
|
1,104 |
1,075 |
$5K |
| 80323 |
|
1,578 |
1,507 |
$4K |
| 80366 |
|
628 |
589 |
$4K |
| 80332 |
|
629 |
589 |
$4K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
4,459 |
3,697 |
$3K |
| 80349 |
|
1,508 |
1,422 |
$2K |
| 83992 |
|
1,504 |
1,419 |
$2K |
| 80365 |
|
599 |
541 |
$2K |
| 80373 |
|
596 |
539 |
$2K |
| 80358 |
|
598 |
542 |
$2K |
| 80354 |
|
595 |
539 |
$2K |
| 80363 |
|
595 |
539 |
$2K |
| 80360 |
|
599 |
541 |
$2K |
| 64445 |
|
48 |
43 |
$2K |
| 80359 |
|
595 |
537 |
$2K |
| J3490 |
Unclassified drugs |
157 |
138 |
$2K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,485 |
1,210 |
$498.85 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
176 |
127 |
$432.81 |
| 20610 |
|
52 |
40 |
$41.84 |
| G8482 |
Influenza immunization administered or previously received |
3,957 |
3,679 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
3,389 |
3,209 |
$0.00 |
| 4004F |
|
1,604 |
1,501 |
$0.00 |
| G9899 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed |
1,873 |
1,724 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
4,872 |
4,405 |
$0.00 |
| 1090F |
|
866 |
801 |
$0.00 |
| 4040F |
|
1,367 |
1,253 |
$0.00 |
| 99490 |
Ccm add 20min |
67 |
54 |
$0.00 |
| G9708 |
Women who had a bilateral mastectomy or who have a history of a bilateral mastectomy or for whom there is evidence of a right and a left unilateral mastectomy |
40 |
40 |
$0.00 |
| 3288F |
|
79 |
61 |
$0.00 |
| 80355 |
|
20 |
17 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
2,283 |
2,100 |
$0.00 |
| 1101F |
|
1,355 |
1,239 |
$0.00 |
| 1036F |
|
2,227 |
2,080 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
1,548 |
1,443 |
$0.00 |
| 3017F |
|
2,937 |
2,733 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
1,636 |
1,516 |
$0.00 |
| 1006F |
|
2,016 |
1,869 |
$0.00 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
57 |
55 |
$0.00 |